Welcome to MacuCLEAR’s FAll View 2010! It has been almost a year since our last issue….and what a year 2010 has been!! MacuCLEAR started 2010 with an acquisition offer of considerable value, and as a blessing in disguise, rejected it in September. Our last “View” mentioned the results of our novel, and successful, Phase Ib/POC human clinical trial. This past May, these clinical results were presented in a peer-reviewed poster session at the 2010 ARVO meeting in Ft. Lauderdale, Florida. We achieved additional patent protection on our intellectual property, and made progress on our US filing. Much of our effort this year has been focused on designing a next phase clinical program that we believe will yield true clinical efficacy data. We have gained considerable traction for our lead drug, MC-1101, from several leading institutions and individuals devoted to finding a treatment for dry AMD. We were invited to and participated in the First Biennial AMD Symposium, and attended the American Association of Ophthalmology meeting. We have secured sufficient new funds to meet the Texas Emerging Technology Fund’s Qualifying Funding Transaction requirement, and have engaged professional sources to help us raise necessary funds for our clinical program. Finally, we have made some necessary changes in our board of directors which prepares MacuCLEAR for its next level of growth. Each of these accomplishments are detailed in respective sections in this newsletter.